Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Retrospective Study Evaluating Hematological Remission Rates and Survival in Chinese Adults with Relapsed or Refractory (r/r) Philadelphia Chromosome Negative (Ph - ) B-Precursor Acute Lymphoblastic Leukemia (ALL)

Jun Ma, MD, Ting Liu, MD, Jie Jin, MD PhD, Jianda Hu, MD PhD, Qifa Liu, MD, Jianxiang Wang, MD, Zhixiang Shen, MD, Xin Du, MD PhD, Bin Jiang, MD, Xianhua Meng, PhD

Blood (2016) 128 (22): 5198.

https://doi.org/10.1182/blood.V128.22.5198.5198

Published: 2016

Journal Articles

Long-Term Safety of Dasatinib in Chinese Chronic Phase Chronic Myeloid Leukemia Patients with Imatinib-Resistance or -Intolerance: Results from a 6-Year Follow-up of a Multicenter Phase II Study

Xiaojun Huang, Qian Jiang, MD, Jianda Hu, MD PhD, Jianyong Li, Jie Jin, MD PhD, Fanyi Meng, Zhixiang Shen, MD, Ting Liu, Depei Wu, MDPhD, Jianmin Wang, Jianxiang Wang

Blood (2016) 128 (22): 1928.

https://doi.org/10.1182/blood.V128.22.1928.1928

Published: 2016

Journal Articles

Retinoic Acid and Arsenic Trioxide with or without Chemotherapy for Acute Promyelocytie Leukemia with Different Risk Stratifications: A Interim Analysis of China APL 2012 Study

Blood (2016) 128 (22): 445.

https://doi.org/10.1182/blood.V128.22.445.445

Published: 2016

Journal Articles

Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Yuankai Shi, MD PhD, Mei Dong, MD, Jun Zhu, MD, Daobin Zhou, MD, Huiqiang Huang, MD, Ping Tu, MD, Weijing Zhang, MD, Xiaonan Hong, MD, Xielan Zhao, MD, Jianfang Sun, MD, Yuehua Liu, MD, Lugui Qiu, MD PhD, ZhiXiang Shen, MD, Jifeng Feng, MD, Xiaoyan Ke, MD PhD

Blood (2015) 126 (23): 1513.

https://doi.org/10.1182/blood.V126.23.1513.1513

Published: 2015

Journal Articles

First-Line Treatment and Management of Chronic Myeloid Leukemia (CML) in Clinical Practice: Update of > 1800 Patients (Pts) in the WORLD CML Registry

Jorge E. Cortes, MD, Ricardo Pasquini, Hagop M. Kantarjian, MD, David Joske, MBBS, FRCPA, FRACP, Luis A Meillon, MD, Zhixiang Shen, MD, Carmen Piccolo, MD, Oleg Zernovak, MD, Ramsathish Sivarathinasami, Dawn F. Eng, Dong-Wook Kim, Timothy P. Hughes, MD, MBBS

Blood (2012) 120 (21): 3750.

https://doi.org/10.1182/blood.V120.21.3750.3750

Published: 2012

Journal Articles

Results of a Randomized, Open-Label, Phase IIIb Study of 2 Schedules of Decitabine in Higher-Risk Myelodysplastic Syndrome Patients

Depei Wu, Xin Du, PhD, Jie Jin, MD, Zhijian Xiao, MD, Zhixiang Shen, MD, Zonghong Shao, MD, Xiao Li, MD, PhD, Xiaojun Huang, Ting Liu, Li Yu, Jianyong Li, MD, PhD, Baoan Chen, Guangsheng He, Zhen Cai, Changgeng Ruan, MD., PhD.

Blood (2012) 120 (21): 3846.

https://doi.org/10.1182/blood.V120.21.3846.3846

Published: 2012

Journal Articles

A Multicenter, Open-Label Study of Posaconazole Oral Suspension in Treatment of Patients with Invasive Fungal Infection Refractory to or Intolerant of First-Line Therapy,

Xiaojun Huang, Fengrong Wang, Yuhong Chen, MD, PhD, Ting Liu, MD, Jianxiang Wang, MD, Jianda Hu, PhD, Jie Jin, MD, Fangping Chen, Shujie Wang, MD, PhD, Zhixiang Shen, MD, PhD, Li Yu, Kang Yu, Yingmin Liang

Blood (2011) 118 (21): 3241.

https://doi.org/10.1182/blood.V118.21.3241.3241

Published: 2011

Journal Articles

Phase 2 Study of Dasatinib in Chinese Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) or Advanced Phase Who Are Resistant to or Intolerant of Imatinib (IM)

Jianxiang Wang, MD, Xiaojun Huang, Jianda Hu, PhD, Jianyong Li, MD, PhD, Jie Jin, MD, Fanyi Meng, MD, Zhixiang Shen, MD, Ting Liu, MD, Depei Wu, MD, Jianmin Wang

Blood (2011) 118 (21): 4434.

https://doi.org/10.1182/blood.V118.21.4434.4434

Published: 2011

Journal Articles

A Multicenter, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Posaconazole Vs Fluconazole in the Prophylaxis of Invasive Fungal Infection in a Chinese Population

Shen Yang, MD, Xiaojun Huang, Jianxiang Wang, MD, Jie Jin, PhD, Jianda Hu, PhD, Kang Yu, Depei Wu, MD, Shujie Wang, MD, PhD, Li Yu, Xiequn Chen, Ting Liu, MD, Yingmin Liang, Chen Fangping, MD, Yan Li, MD, Zhixiang Shen, MD, PhD

Blood (2011) 118 (21): 4916.

https://doi.org/10.1182/blood.V118.21.4916.4916

Published: 2011

Journal Articles

Survival Outcomes of Hematopoietic Stem Cell Transplantation (HSCT) and Imatinib in the Treatment of Chronic Myeloid Leukemia Treatment in China: a Meta-Analysis.

Xiaojun Huang, MD, PhD, Zhixiang Shen, MD, PhD, Zi Chen, Yang Cao, MD, Ph.D., Xiaoping Xu, MD, Ph.D., Qiang Wang, Ph.D., Samara Mendes de Costa, Henry Dummett, Jie Chen, MD, Ph.D.

Blood (2009) 114 (22): 2497.

https://doi.org/10.1182/blood.V114.22.2497.2497

Published: 2009

Journal Articles

A Worldwide Observational Registry Collecting Longitudinal Data On the Management of CML Patients (The WORLD CML Registry) - Summary of the First 1001 Patients.

Ricardo Pasquini, MD, Jorge Cortes-Franco, MD, Hagop M. Kantarjian, MD, David Joske, MBBS, FRCPA, FRACP, Zhixiang Shen, MD, PhD, Luis Meillon, MD, Lidia Mongay, MD, PhD, MBA, Dawn F. Eng, Jim Wang, PhD, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD

Blood (2009) 114 (22): 4267.

https://doi.org/10.1182/blood.V114.22.4267.4267

Published: 2009

Journal Articles

Cost-Effectiveness of Imatinib in Comparison with Bone Marrow Transplant in Chronic Phase (CP) Chronic Myeloid Leukaemia (CML) in China.

Zhixiang Shen, MD, PhD, Xiaojun Huang, MD, PhD, Samara Mendes de Costa, Zi Chen, Xiaoping Xu, MD, Ph.D., Qiang Wang, Ph.D., Jie Chen, MD, Ph.D.

Blood (2009) 114 (22): 2474.

https://doi.org/10.1182/blood.V114.22.2474.2474

Published: 2009

Journal Articles

Expanding Nilotinib Access in Clinical Trials (ENACT) Study in Adult Patients (Pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Blast Crisis (BC), Accelerated Phase (AP), or Chronic Phase (CP): Preliminary Safety Analysis.

Franck Nicolini, MD, Giuliana Alimena, MD, Haifa-Kathrin Al-Ali, MD, Andrey Zaritskey, Zhixiang Shen, MD, Saengsuree Jootar, MD, Graeme Smith, MD, Yanzhi Hsu, Maria Luisa Veronese, David A. Rizzieri

Blood (2007) 110 (11): 2960.

https://doi.org/10.1182/blood.V110.11.2960.2960

Published: 2007

Journal Articles

An Open-Label Study of Pegylated Liposomal Doxorubicin, Vincristine and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in Chinese Population.

Yang Shen, MD, Zhixiang Shen, MD, Bin Jiang, MD, Jian Hou, MD, Rong Zhan, MD, Lugui Qiu, MD, Yongji Wu, MD, Jie Jin, MD, Juan Li, MD, Fanyi Meng, MD, Ping Zou, MD, Ting Liu, MD, Jianyong Li, MD, Chun Wang, MD, Depai Wu, MD, Jun Ma, MD

Blood (2007) 110 (11): 4816.

https://doi.org/10.1182/blood.V110.11.4816.4816

Published: 2007

NARROW

Retrospective Study Evaluating Hematological Remission Rates and Survival in Chinese Adults with Relapsed or Refractory (r/r) Philadelphia Chromosome Negative (Ph - ) B-Precursor Acute Lymphoblastic Leukemia (ALL)

Long-Term Safety of Dasatinib in Chinese Chronic Phase Chronic Myeloid Leukemia Patients with Imatinib-Resistance or -Intolerance: Results from a 6-Year Follow-up of a Multicenter Phase II Study

Retinoic Acid and Arsenic Trioxide with or without Chemotherapy for Acute Promyelocytie Leukemia with Different Risk Stratifications: A Interim Analysis of China APL 2012 Study

Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

First-Line Treatment and Management of Chronic Myeloid Leukemia (CML) in Clinical Practice: Update of > 1800 Patients (Pts) in the WORLD CML Registry

Results of a Randomized, Open-Label, Phase IIIb Study of 2 Schedules of Decitabine in Higher-Risk Myelodysplastic Syndrome Patients

A Multicenter, Open-Label Study of Posaconazole Oral Suspension in Treatment of Patients with Invasive Fungal Infection Refractory to or Intolerant of First-Line Therapy,

Phase 2 Study of Dasatinib in Chinese Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) or Advanced Phase Who Are Resistant to or Intolerant of Imatinib (IM)

A Multicenter, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Posaconazole Vs Fluconazole in the Prophylaxis of Invasive Fungal Infection in a Chinese Population

Survival Outcomes of Hematopoietic Stem Cell Transplantation (HSCT) and Imatinib in the Treatment of Chronic Myeloid Leukemia Treatment in China: a Meta-Analysis.

A Worldwide Observational Registry Collecting Longitudinal Data On the Management of CML Patients (The WORLD CML Registry) - Summary of the First 1001 Patients.

Cost-Effectiveness of Imatinib in Comparison with Bone Marrow Transplant in Chronic Phase (CP) Chronic Myeloid Leukaemia (CML) in China.

Expanding Nilotinib Access in Clinical Trials (ENACT) Study in Adult Patients (Pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Blast Crisis (BC), Accelerated Phase (AP), or Chronic Phase (CP): Preliminary Safety Analysis.

An Open-Label Study of Pegylated Liposomal Doxorubicin, Vincristine and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in Chinese Population.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only